Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bethel, A.
Right arrow Articles by Traystman, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bethel, A.
Right arrow Articles by Traystman, R. J.
Right arrowPubmed/NCBI databases
*Substance via MeSH

(Stroke. 1997;28:609-616.)
© 1997 American Heart Association, Inc.


Articles

Intravenous Basic Fibroblast Growth Factor Decreases Brain Injury Resulting From Focal Ischemia in Cats

Ameil Bethel, MD; Jeffrey R. Kirsch, MD; Raymond C. Koehler, PhD; Seth P. Finklestein, MD; Richard J. Traystman, PhD

From the Department of Anesthesiology and Critical Care Medicine, The Johns Hopkins Medical Institutions, Baltimore, Md, and Department of Neurology, Massachusetts General Hospital, Boston, Mass (S.P.F.).

Correspondence to Richard J. Traystman, PhD, Department of Anesthesiology and Critical Care Medicine, The Johns Hopkins Medical Institutions, 600 N Wolfe St, Blalock 1408, Baltimore, MD 21287. E-mail rjtrayst{at}gwgate1.jhmi.jhu.edu.

Background and Purpose We tested the hypothesis that intravenous administration of basic fibroblast growth factor (bFGF) during 4 hours of permanent focal ischemia would affect acute brain injury.

Methods Halothane-anesthetized cats underwent left middle cerebral artery (MCA) occlusion for 4 hours. Control cats received diluent (n=14). Experimental cats were treated with bFGF at a rate of 5 (n=13), 50 (n=13), or 250 µg/kg per hour (n=9) intravenously beginning 60 minutes after initiation of ischemia and continuing until the end of the protocol.

Results As measured by the microsphere method, blood flow to ipsilateral caudate nucleus and ipsilateral inferior temporal cortex was decreased similarly during ischemia, before drug administration, in all groups. Likewise, there was no difference in blood flow to ipsilateral caudate nucleus or inferior temporal cortex as a result of bFGF administration during MCA occlusion. Triphenyltetrazolium-determined injury volume of the ipsilateral cerebral cortex (control, 40±7%; bFGF 5 µg/kg per hour, 22±5%; bFGF 50 µg/kg per hour, 26±7%; bFGF 255 µg/kg per hour, 23±6% of ipsilateral cerebral cortex; mean±SEM) was less in cats treated with bFGF. There was no difference among groups in injury volume to caudate nucleus (control, 29±8%; bFGF 5 µg/kg per hour, 29±8%; bFGF 50 µg/kg per hour, 21±7%; bFGF 250 µg/kg per hour, 32±7% of ipsilateral caudate nucleus). Somatosensory evoked potential amplitude decreased similarly (to <20% of baseline amplitude in all groups) during MCA occlusion and was not altered by bFGF administration.

Conclusions These data indicate that systemic administration of bFGF ameliorates acute injury in the cerebral cortex without increasing blood flow during focal ischemia in cats. Because bFGF afforded protection when administered after the onset of ischemia, bFGF may provide its beneficial effect by limiting progression of injury in ischemic border regions.


Key Words: cerebral blood flow • growth factors • middle cerebral artery occlusion • neuroprotection • somatosensory evoked potentials • cats




This article has been cited by other articles:


Home page
J. Neurosci.Home page
P. Li and T. H. Murphy
Two-Photon Imaging during Prolonged Middle Cerebral Artery Occlusion in Mice Reveals Recovery of Dendritic Structure after Reperfusion
J. Neurosci., November 12, 2008; 28(46): 11970 - 11979.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
A. Wagle and J. P. Singh
Fibroblast Growth Factor Protects Nitric Oxide-Induced Apoptosis in Neuronal SHSY-5Y Cells
J. Pharmacol. Exp. Ther., December 1, 2000; 295(3): 889 - 895.
[Abstract] [Full Text]


Home page
J. Neurosci.Home page
J. P. Wagner, I. B. Black, and E. DiCicco-Bloom
Stimulation of Neonatal and Adult Brain Neurogenesis by Subcutaneous Injection of Basic Fibroblast Growth Factor
J. Neurosci., July 15, 1999; 19(14): 6006 - 6016.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
W. R. Schabitz, F. Li, K. Irie, B. W. Sandage Jr, K. W. Locke, M. Fisher, and P. D. Hurn
Synergistic Effects of a Combination of Low-Dose Basic Fibroblast Growth Factor and Citicoline After Temporary Experimental Focal Ischemia • Editorial Comment
Stroke, February 1, 1999; 30(2): 427 - 432.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
T. Kawamata, W. D. Dietrich, T. Schallert, J. E. Gotts, R. R. Cocke, L. I. Benowitz, and S. P. Finklestein
Intracisternal basic fibroblast growth factor enhances functional recovery and up-regulates the expression of a molecular marker of neuronal sprouting following focal cerebral infarction
PNAS, July 22, 1997; 94(15): 8179 - 8184.
[Abstract] [Full Text] [PDF]


Home page
NeuroscientistHome page
D. A. Lin and S. P. Finklestein
{blacksquare} REVIEW : Basic Fibroblast Growth Factor: A Treatment for stroke?
Neuroscientist, July 1, 1997; 3(4): 247 - 250.
[Abstract] [PDF]